The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients

Clinical and Experimental Nephrology

Volumn 17, Issue 1, 2013, Pages 127-133

  Yoshimura, Norio ^a   Ushigome, Hidetaka ^a   Akioka, Kiyokazu ^a   Nobori, Syuuji ^a   Suzuki, Tomoyuki ^a   Sakai, Kazuki ^a   Okamoto, Masahiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Acute rejection; CMV infection; High dose mizoribine

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; GANCICLOVIR; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HUMAN; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION; MALE; NAUSEA; PATIENT SATISFACTION; POLYOMAVIRUS INFECTION; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CREATININE; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RIBONUCLEOSIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874106652     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0669-4     Document Type: Article

References (15)

1. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Asano K, et al. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot. 1974;27:775-82.
2. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575-97.
3. Inou T. Immunosuppressive effects of bredinin on renal transplantation (in Japanese). Jpn J Transplant (Tokyo). 1982;17(suppl):547-61.
4. Inou T, Kusaba R, Takahashi I, Sugimoto H, Kuzuhara K, Yamada Y, et al. Clinical trial of bredinin in renal transplantation. Transpl Proc. 1981;13:315-8.
5. Amemiya H, Suzuki S, Niiya S, Watanabe H, Kotake T. Synergistic effect of cyclosporine and mizoribine on survival of dog renal allografts. Transplantation. 1988;46:768-71.
6. Hosokawa S, Ogino T, Ihara H, Shimada K, Arima M, Ikoma F, et al. Triple-drug therapy with mizoribine, cyclosporine and methylprednisolone (in Japanese). Jpn J Transplant. 1989;24:21-7.
7. Hosotsubo H, Takahara S, Taenaka N. Simplified high-performance liquid chromatographic method for determination of mizoribine in human serum. J Chromatogr. 1988;432:340-5.
8. Tanabe K, Tokumoto T, Ishikawa N, Kanematsu A, Oshima T, Harano M, et al. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppressant. Transpl Proc. 1999;31:2877-9.
9. Sonda K, Takahashi K, Tanabe K, Fuchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transpl Proc. 1996;28:3643-8.
10. Tanabe K. Re-evaluation of mizoribine for renal transplantation (Japanese). Ther Res. 2002;23:992-7.
11. Akiyama T, Okazaki H, Takahashi K, Hasegawa A, Tanabe K, Uchida K, et al. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation. Transpl Proc. 2005;37:843-5.
12. Basic-Jukic N, Kes P, Bubic-Filipi LJ, Puretic Z, Brunetta B, Pasini J. Does mycophenolate mofetil increases the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation. Transpl Proc. 2005;37:850-1.
13. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transpl. 2000;14:136-8.
14. Shiraki K, Ishibashi M, Okuno T, Kokado Y, Takahara S, Yamanishi K, et al. Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus. Transpl Proc. 1990;22:1682-5.
15. Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transpl Proc. 2008;40:2262-7.